- Home
- GBR vs ONCO Comparison
GBR vs ONCO Comparison
Compare GBR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | ONCO |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GBR | ONCO |
|---|---|---|
| Price | $0.64 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.5K | ★ 416.0K |
| Earning Date | 05-14-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | $155,000.00 | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.16 | N/A |
| 52 Week Low | $0.62 | $0.09 |
| 52 Week High | $1.31 | $6.73 |
Technical Indicators
Market Signals| Indicator | GBR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 39.27 |
| Support Level | N/A | $0.60 |
| Resistance Level | $0.84 | $0.91 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 15.50 | 2.81 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.